Can-Fite BioPharma ( (CANF) ) just unveiled an update.
Can-Fite BioPharma Ltd. (NYSE: CANF) shares were lower Tuesday. The Israeli-based company, a clinical-stage biotechnology ...
Namodenoson’s Favorable Safety Profile and Broad Patent Portfolio Positions it as a Promising Candidate in the Growing Obesity Treatment Market ...
Namodenoson’s oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity ...
Namodenoson Provided Clinical Stabilization as a Potential Bridge to Transplant in Advanced Liver Failure Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: ...
Namodenoson's oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can- ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs ...
Can-Fite BioPharma Ltd. (NYSE American:CANF) announced Monday that it will hold a Special General Meeting of Shareholders on March 3, 2026, at its offices in Ramat Gan, Israel. The meeting will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results